NN Investment Partners Holdings N.V. Has $165 Million Stock Position in PRA Health Sciences, Inc. (NASDAQ:PRAH)
NN Investment Partners Holdings N.V. decreased its holdings in shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) by 23.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,076,120 shares of the medical research company’s stock after selling 330,073 shares during the quarter. PRA Health Sciences makes up about 1.0% of NN Investment Partners Holdings N.V.’s holdings, making the stock its 22nd biggest position. NN Investment Partners Holdings N.V. owned approximately 1.67% of PRA Health Sciences worth $165,003,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of PRAH. International Assets Investment Management LLC acquired a new stake in PRA Health Sciences in the 4th quarter worth $61,000. Fieldpoint Private Securities LLC raised its stake in shares of PRA Health Sciences by 1,078.7% in the first quarter. Fieldpoint Private Securities LLC now owns 884 shares of the medical research company’s stock worth $136,000 after acquiring an additional 809 shares during the last quarter. Panagora Asset Management Inc. raised its stake in shares of PRA Health Sciences by 14.1% in the fourth quarter. Panagora Asset Management Inc. now owns 1,208 shares of the medical research company’s stock worth $152,000 after acquiring an additional 149 shares during the last quarter. JustInvest LLC bought a new position in shares of PRA Health Sciences in the first quarter worth about $208,000. Finally, Boenning & Scattergood Inc. bought a new position in shares of PRA Health Sciences in the first quarter worth about $210,000. Institutional investors and hedge funds own 96.14% of the company’s stock.
In related news, CFO Michael J. Bonello sold 2,048 shares of the company’s stock in a transaction dated Monday, April 26th. The shares were sold at an average price of $166.77, for a total transaction of $341,544.96. Following the completion of the sale, the chief financial officer now owns 19,228 shares of the company’s stock, valued at $3,206,653.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.30% of the company’s stock.
PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Wednesday, April 28th. The medical research company reported $1.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.03. PRA Health Sciences had a net margin of 7.09% and a return on equity of 22.21%. The business had revenue of $933.78 million for the quarter, compared to the consensus estimate of $863.45 million. During the same period in the prior year, the company posted $1.05 earnings per share. PRA Health Sciences’s revenue was up 19.1% compared to the same quarter last year. On average, research analysts forecast that PRA Health Sciences, Inc. will post 3.85 earnings per share for the current year.
A number of equities analysts have weighed in on the stock. KeyCorp reaffirmed a “sector weight” rating on shares of PRA Health Sciences in a research note on Monday, March 15th. Mizuho boosted their target price on shares of PRA Health Sciences from $110.00 to $155.00 in a research note on Friday, March 19th. Robert W. Baird reaffirmed a “neutral” rating and set a $165.00 price target on shares of PRA Health Sciences in a research report on Monday, April 26th. Credit Suisse Group upped their price target on shares of PRA Health Sciences from $159.00 to $169.00 and gave the stock an “outperform” rating in a research report on Thursday, April 29th. Finally, Zacks Investment Research raised shares of PRA Health Sciences from a “sell” rating to a “hold” rating and set a $160.00 price target on the stock in a research report on Tuesday, March 30th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $134.13.
PRA Health Sciences Profile
PRA Health Sciences, Inc engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It operates through Clinical Research and Data Solutions segment. The Clinical Research segment serves biopharmaceutical clients and offers outsourced clinical research and clinical trial related services.
Recommended Story: Support Level
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.